Condition
Toxic Shock Syndrome
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07199998Recruiting
Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota
NCT02219165Phase 2CompletedPrimary
Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study
NCT02814708Phase 2CompletedPrimary
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
NCT02340338Phase 1CompletedPrimary
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Showing all 4 trials